Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013715 | 0.86 | CSNK2A1 (0.53) | TAAR1LOXL2CSNK2A1 | |
| Hydrochloric Acid SCHEMBL1015839 | 0.84 | CSNK2A1 (0.55) | TAAR1LOXL2CSNK2A1 | |
| SCHEMBL15244883 | 0.79 | TAAR1 (0.63) | HTR7TAAR1DRD2DRD1MAOB | |
| SCHEMBL15349962 | 0.79 | FYN (0.54) | — | |
| SCHEMBL16160786 | 0.79 | BCL2 (0.47) | SMN1; SMN2 | |
| SCHEMBL420379 | 0.78 | PPARD (0.54) | — | |
| SCHEMBL172787 | 0.77 | TAAR1 (0.62) | HTR7TAAR1DRD2DRD1MAOB | |
| Hydrochloric Acid SCHEMBL27718613 | 0.76 | HTR7 (0.61) | HTR7TAAR1DRD2DRD1MAOB | |
| SCHEMBL15525063 | 0.74 | MAOA (0.47) | MAOBCSNK2A1 | |
| SCHEMBL422337 | 0.73 | GRIN2D (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | HTR7 1185/4885TAAR1 4720/4885DRD2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.